Piper Sandler Lowers Nyxoah (NASDAQ:NYXH) Price Target to $10.00

Nyxoah (NASDAQ:NYXH) had its target price cut by stock analysts at Piper Sandler from $11.00 to $10.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s target price suggests a potential upside of 104.92% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Nyxoah in a report on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price target on shares of Nyxoah in a report on Tuesday, September 26th. Robert W. Baird assumed coverage on Nyxoah in a research report on Tuesday, July 18th. They set a “neutral” rating on the stock. Finally, Stifel Nicolaus decreased their price target on shares of Nyxoah from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.50.

Nyxoah Stock Performance

NASDAQ:NYXH opened at $4.88 on Thursday. The stock has a market cap of $121.71 million, a P/E ratio of -2.73 and a beta of 1.44. The company has a current ratio of 5.99, a quick ratio of 5.92 and a debt-to-equity ratio of 0.10. The stock’s 50-day moving average is $6.80 and its 200-day moving average is $7.56. Nyxoah has a 1-year low of $4.36 and a 1-year high of $10.34.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Tuesday, August 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). Nyxoah had a negative net margin of 1,191.93% and a negative return on equity of 37.65%. The company had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.04 million. Equities research analysts anticipate that Nyxoah will post -1.92 earnings per share for the current year.

Hedge Funds Weigh In On Nyxoah

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. bought a new position in shares of Nyxoah during the first quarter valued at about $8,177,000. Sio Capital Management LLC boosted its stake in shares of Nyxoah by 1,072.4% in the 1st quarter. Sio Capital Management LLC now owns 188,875 shares of the company’s stock worth $1,411,000 after buying an additional 172,765 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Nyxoah in the 1st quarter worth approximately $965,000. Sei Investments Co. bought a new position in shares of Nyxoah in the second quarter valued at approximately $265,000. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of Nyxoah during the first quarter valued at approximately $97,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.